This page catalogs biotechnology and pharmaceutical companies developing gene therapy and genome editing approaches for Alzheimer's disease (AD). These technologies include AAV-based gene delivery, CRISPR-Cas9 genome editing, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and prime editing — representing next-generation therapeutic strategies targeting the underlying genetic and molecular causes of AD.
| Technology | Description | Advantages | Companies |
|------------|-------------|------------|-----------|
| AAV Gene Therapy | Adeno-associated virus vectors delivering therapeutic genes | Long-term expression, safety profile, CNS penetration | Voyager, Lexeo, uniQure, Spark, Prevail |
| CRISPR-Cas9 | RNA-guided genome editing | Precise targeting, versatility | Intellia, CRISPR Therapeutics, Ntla |
| Zinc Finger Nucleases | Engineered protein-based editing | Well-characterized, lower immunogenicity | Sangamo Therapeutics |
| TALENs | Transcription activator-like effector nucleases | High specificity, large cargo capacity | Various research programs |
| Prime Editing | Next-gen precision editing | Minimal DNA double-strand breaks | Intellia, CRISPR Therapeutics |
Status: Phase 1/2 (LEAD trial)
Lexeo Therapeutics is a clinical-stage gene therapy company with a lead program targeting APOE4 homozygous Alzheimer's disease. Their LX1001 program delivers the protective APOE2 gene via AAV intrathecal administration.
Status: Preclinical
Voyager Therapeutics is developing AAV-based gene therapies for Alzheimer's disease, including VY-TAU targeting tau pathology and VY-ABCA1 targeting apoE metabolism.
Status: Preclinical
Prevail Therapeutics, acquired by Eli Lilly in 2021 for $880 million, focuses on gene therapy approaches for neurodegenerative diseases including GBA1-related AD.
Status: Research
uniQure is a gene therapy company with expertise in AAV delivery and CNS programs, developing therapies for Huntington's disease with potential applications in AD.
Status: Research
Spark Therapeutics, now part of Roche, pioneered AAV gene therapy for inherited retinal diseases and is expanding into CNS applications.
Status: Preclinical / Research
Intellia Therapeutics is a leader in CRISPR-Cas9 genome editing, developing in vivo therapeutic programs using lipid nanoparticle (LNP) delivery for CNS applications.
Status: Preclinical
CRISPR Therapeutics (NASDAQ: CRSP) is focused on developing CRISPR-Cas9 based therapies, including ex vivo editing approaches for immune cell therapies and in vivo applications.
Status: Discovery
Ntla (formerly Metagen Therapeutics) is developing genome editing technologies with applications in neurodegenerative diseases, focusing on novel delivery methods.
Status: Research
Bluebird Bio is a gene therapy company with expertise in lentiviral and AAV delivery, applying their platform to CNS disorders.
Status: Preclinical / Phase 1
Sangamo Therapeutics is a pioneer in zinc finger nuclease (ZFN) technology, with programs in CNS gene therapy including tau targeting.
Status: Discovery / Research
Remi Biopharma is developing next-generation genome editing approaches for CNS diseases, with a focus on precise editing technologies.
| Serotype | CNS Tropism | Usage |
|----------|-----------|-------|
| AAV9 | High | Most common for CNS delivery |
| AAVrh.10 | High | Alternative serotype |
| AAV-PHP.B | Very High | Enhanced CNS Penetration |
| AAV-PHP.S | High | Vascular delivery |
| Technology | Precision | Efficiency | Immunogenicity | Cargo Size |
|------------|-----------|-----------|-----------------|-------------|
| CRISPR-Cas9 | High | High | Low | ~4.5 kb |
| CRISPR-Cas12 | High | High | Low | ~4.5 kb |
| CRISPR-Cas13 | High | Moderate | Low | ~3.5 kb |
| ZFN | Moderate | High | Moderate | ~1.8 kb |
| TALEN | High | Moderate | Low | ~3.3 kb |
| Target | Role | Companies |
|--------|------|-----------|
| APOE2/APOE4 | Lipid metabolism, amyloid clearance | Lexeo |
| AADC | Dopamine synthesis | Voyager (PD focus) |
| BDNF | Neurotrophic factor | Various |
| NGF | Cholinergic neuron support | Various |
| TREM2 | Microglial function | Denali, others |
| Target | Rationale | Companies |
|--------|----------|-----------|
| APP | Reduce Aβ production | Research |
| BACE1 | Reduce Aβ generation | Research |
| Tau (MAPT) | Reduce tau pathology | Voyager, Sangamo |
| GBA1 | Lysosomal function | Prevail |
| Company | Program | Target | Stage | Trial ID |
|---------|---------|--------|-------|----------|
| Lexeo | LX1001 | APOE4 | Phase 1/2 | NCT03634007 |
| Voyager | VY-TAU | Tau | Preclinical | - |
| Voyager | VY-ABCA1 | apoE | Discovery | - |
| Company | Technology | Target | Stage |
|---------|-----------|--------|-------|
| Intellia | CRISPR | CNS targets | Discovery |
| Sangamo | ZFN | Tau | Preclinical |
| Ntla | Novel | CNS | Discovery |
| Company | Platform | Technology | Development Stage | Key Target |
|---------|----------|-----------|-----------------|------------|
| Lexeo Therapeutics | AAV | Gene replacement | Phase 1/2 | APOE4 |
| Voyager Therapeutics | AAV | Gene therapy | Preclinical | Tau, ABCA1 |
| Prevail Therapeutics | AAV | Gene therapy | Preclinical | GBA1 |
| uniQure | AAV | Gene therapy | Research | Various CNS |
| Spark Therapeutics | AAV | Gene therapy | Research | CNS |
| Intellia Therapeutics | CRISPR | Genome editing | Discovery | CNS targets |
| CRISPR Therapeutics | CRISPR | Genome editing | Preclinical | Various |
| Sangamo Therapeutics | ZFN | Genome editing | Preclinical | Tau |
| Ntla | Novel | Genome editing | Discovery | CNS |
| Bluebird Bio | Lentiviral/AAV | Gene therapy | Research | CNS |